DeutschNewstral
Article
syndication.washingtonpost.com on 2023-11-08 20:31
Eli Lilly wins FDA nod for obesity drug that rivals Wegovy, Ozempic - Wed, 08 Nov 2023 PST
Related news
- TOzempic & Wegovytheava.com
Pharmaceuticals sector: Approval for Eli Lilly obesity drug sets up rival to WegovyFinancial Times- IEli Lilly to expand in obesity drugs with $1.925 billion acquisition of Versanis Bioinvezz.com
Obesity drug shows promise, Eli Lilly saysArkansas Online
Eli Lilly’s new weight loss drug could drive down prices of Wegovy and OzempicDallas News- Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss marketFinancial Times
- FEli Lilly & Co: Eli Lilly predicts sales jump from obesity drug demandft.com
- IEli Lilly stock price forecast ahead of obesity drug approvalinvezz.com
Eli Lilly launches website, home delivery option for Wegovy alternative ZepboundNew York Post- TNovo Nordisk, Eli Lilly leap as Ozempic show promise in kidney patient treatmentthestreet.com
Eli Lillymichronicleonline.com
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early TrialForbes
Eli Lilly, Urban Outfitters skid; Deere climbsThe Salt Lake Tribune- Ozempic And Wegovy Not Linked To Uptick In Suicidal Thoughts, Study FindsForbes
Weight-Loss Drugs Ozempic and Wegovy Can Also Protect the HeartWired.com
New study ties weight-loss drugs Wegovy, Ozempic to serious gastrointestinal conditionsCBC- Eli Lilly achieves hard-won success with Alzheimer’s and obesity drugsFinancial Times
- FEli Lilly says obesity drug’s results compare to weight-loss surgeryft.com
- Ozempic, Wegovy demand drives up illegal sales of weight-loss drugsNew York Post